Private Trust Co. NA Sells 77 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Private Trust Co. NA lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 145 shares of the biopharmaceutical company’s stock after selling 77 shares during the quarter. Private Trust Co. NA’s holdings in Regeneron Pharmaceuticals were worth $103,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Proficio Capital Partners LLC boosted its position in Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth $127,489,000. KBC Group NV boosted its holdings in shares of Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares during the period. Icon Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after buying an additional 75,569 shares during the last quarter. Finally, State Street Corp raised its holdings in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $675.49 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $73.85 billion, a PE ratio of 17.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company’s 50-day moving average price is $697.13 and its two-hundred day moving average price is $859.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $11.86 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.